Leilei Fu
Impact in
- Geriatrics and Gerontology top 1%
- Sirtuins and Resveratrol in Medicine
- Cancer Research top 5%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
Papers in
-
- Ubiquitin and proteasome pathways 7
- Protein Degradation and Inhibitors 6
- Melanoma and MAPK Pathways 5
- PI3K/AKT/mTOR signaling in cancer 4
- Epidemiology 24
- Autophagy in Disease and Therapy 19
- Hepatitis B Virus Studies 4
- Co-authors
- Bo Liu (11 shared papers)Liang Ouyang (15 shared papers)Lan Zhang (16 shared papers)Yi Chen (3 shared papers)Cheng Peng (3 shared papers)Bo Han (3 shared papers)Minru Liao (3 shared papers)Peng Fu (2 shared papers)
- Journals
- European Journal of Medicinal Chemistry (6 papers)Journal of Medicinal Chemistry (5 papers)Cell Proliferation (4 papers)Oncotarget (4 papers)APOPTOSIS (4 papers)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Leilei Fu
56 papers receiving 2.9k citations
Leilei Fu's Hit Papers
Peers
Comparison fields: 5 of 123
- Geriatrics and Gerontology 217
- Cancer Research 469
- Physiology 152
- Epidemiology 771
- Molecular Biology 1.6k
Countries citing papers authored by Leilei Fu
This map shows the geographic impact of Leilei Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leilei Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leilei Fu more than expected).
Fields of papers citing papers by Leilei Fu
This network shows the impact of papers produced by Leilei Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leilei Fu. The network helps show where Leilei Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Leilei Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Regulated cell death (RCD) in cancer: key pathways and targeted therapies Hit paper breakdown → | 2022 | 579 |
| 2 | 2014 | 185 | |
| 3 | 2015 | 182 | |
| 4 | 2013 | 172 | |
| 5 | 2011 | 156 | |
| 6 | 2012 | 130 | |
| 7 | 2017 | 126 | |
| 8 | 2020 | 95 | |
| 9 | 2018 | 88 | |
| 10 | 2017 | 81 | |
| 11 | 2016 | 75 | |
| 12 | 2014 | 69 | |
| 13 | 2020 | 65 | |
| 14 | 2-APQC, a small-molecule activator of Sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis Hit paper breakdown → | 2024 | 64 |
| 15 | 2018 | 62 | |
| 16 | 2021 | 53 | |
| 17 | 2024 | 51 | |
| 18 | 2022 | 46 | |
| 19 | 2017 | 41 | |
| 20 | 2020 | 39 |
About Leilei Fu
Leilei Fu is a scholar working on Molecular Biology, Epidemiology, Oncology, Computational Theory and Mathematics and Pathology and Forensic Medicine, having authored 59 papers that have together received 2.9k indexed citations. Recurring topics across this work include Autophagy in Disease and Therapy (19 papers), Computational Drug Discovery Methods (9 papers), Ubiquitin and proteasome pathways (7 papers), Protein Degradation and Inhibitors (6 papers), Melanoma and MAPK Pathways (5 papers), Hepatitis B Virus Studies (4 papers), Cancer Mechanisms and Therapy (4 papers) and PI3K/AKT/mTOR signaling in cancer (4 papers). The work is most often cited by research in Geriatrics and Gerontology (217 citations), Cancer Research (469 citations), Physiology (152 citations), Epidemiology (771 citations) and Molecular Biology (1.6k citations). Leilei Fu has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Bo Liu, Liang Ouyang, Lan Zhang, Yi Chen, Cheng Peng, Bo Han, Minru Liao, Peng Fu, Rui Qin and Shiou Zhu. Their work appears in journals such as European Journal of Medicinal Chemistry, Journal of Medicinal Chemistry, Cell Proliferation, Oncotarget and APOPTOSIS.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.